-
ILCSC Session Highlight: Histological Transformation of NSCLC into SCLC
Do you want to learn more about NSCLC transformation to SCLC? Join us for the International Lung Cancer Survivorship Conference and tune into Dr. Triparna Sen's (Icahn School of Medicine at Mount...
IN THE SPOTLIGHT
-
ILCSC Session Highlight: Addressing Brain Mets in Lung Cancer
Leading lung cancer expert Dr. Manmeet Ahluwalia (Miami Cancer Institute) discusses brain metastases in people living with lung cancer. Register for free for the virtual... -
Decentralized Trials: Bringing Clinical Trials Closer to the Patient
While participating in clinical trials can provide substantial benefits to people with lung cancer, the resources required to do so may pose significant hurdles, especially to... -
LUNGevity's International Lung Cancer Survivorship Conference
LUNGevity's 2023 International Lung Cancer Survivorship Conference features something for everyone! Our lineup of internationally renowned lung cancer experts will be covering a... -
ALK Virtual Meetup
ALK patients/survivors - Join us the 4th Wednesday of every month to connect with others who share common experiences and build your community. -
2023 ASCO: Highlights of Lung Cancer Research
Recently, members of LUNGevity Foundation joined thousands of attendees from the US and around the world, including oncologists, scientists, biotech and pharmaceutical... -
Navigating Hope: How Comprehensive Biomarker Testing is Guiding Lung Cancer Care
Join us for a discussion on lung cancer biomarkers to learn what biomarker testing is, why it’s important, and how it can be used to optimize your treatment plans. We are thrilled... -
Tracing the Clues of a Global Killer: How Dr. Charles Swanton’s Research Is Shedding New Light on Lung Cancer
As Chief Investigator of the groundbreaking Cancer Research UK (CRUK) TRACERx study, you could say that Dr. Charles Swanton is having a moment. Launched nine years ago, TRACERx... -
What the End of the COVID Public Health Emergency Means for You
It’s been more than 3 years since the US Department of Health and Human Services (HHS) first declared a nationwide Public Health Emergency (PHE) due to COVID-19. Since then... -
The Importance of Follow-up Screening
Terri Ann DiJulio, a long-time lung cancer survivor who has overcome three lung cancer diagnoses, talks about the importance of follow-up screenings for lung cancer, family history...
ILCSC Session Highlight: Histological Transformation of NSCLC into SCLC
ILCSC Session Highlight: Histological Transformation of NSCLC into SCLC
Do you want to learn more about NSCLC transformation to SCLC? Join us for the International Lung Cancer Survivorship Conference and tune into Dr. Triparna Sen's (Icahn School of Medicine at Mount Sinai) session. Registration is free for lung cancer patients, survivors, and care partners to attend this virtual event.
Alectinib shows promise in early-stage ALK-positive non-small cell lung cancer
Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC
Phase 3 Trial Results Show Adjuvant Alectinib Reduces Recurrence, Mortality in Early-Stage ALK-Positive NSCLC
Phase 3 Trial Results Show Adjuvant Alectinib Reduces Recurrence, Mortality in Early-Stage ALK-Positive NSCLC
Lung cancer biomarker campaign, launched with AstraZeneca, boosts its reach and adds pharma supporters
Lung cancer biomarker campaign, launched with AstraZeneca, boosts its reach and adds pharma supporters
Alectinib Meets DFS End Point in ALK+ Early-Stage NSCLC
Trial-first for Roche lung cancer ALK inhibitor
Following in Tecentriq's footsteps, Alecensa gives Roche another win in early-stage lung cancer
Following in Tecentriq's footsteps, Alecensa gives Roche another win in early-stage lung cancer
Genentech's Alecensa shows promise in Phase III study for early-stage ALK-positive lung cancer
Genentech's Alecensa shows promise in Phase III study for early-stage ALK-positive lung cancer
Roche claims study success for targeted drug in early lung cancer
Decentralized Trials: Bringing Clinical Trials Closer to the Patient
Decentralized Trials: Bringing Clinical Trials Closer to the Patient
While participating in clinical trials can provide substantial benefits to people with lung cancer, the resources required to do so may pose significant hurdles, especially to those who don’t live close to where trials are held, such as academic medical centers or major oncology network sites. Decentralized clinical trials remove some hurdles to trial participation for patients and are thus important for improving trial access for larger and more diverse groups of people. The U.S. Food and Drug…
LUNGevity's International Lung Cancer Survivorship Conference
LUNGevity's International Lung Cancer Survivorship Conference
LUNGevity's 2023 International Lung Cancer Survivorship Conference features something for everyone! Our lineup of internationally renowned lung cancer experts will be covering a diverse range of topics, including how air pollution may contribute to lung cancer development, advances in early-stage treatment, the role of integrative medicine and complementary medicine approaches in disease management, addressing brain metastases, and tackling the challenge of histological transformation from…
A Look at NSCLC and Its Current and Emerging Therapies
2023 ASCO: Highlights of Lung Cancer Research
2023 ASCO: Highlights of Lung Cancer Research
Recently, members of LUNGevity Foundation joined thousands of attendees from the US and around the world, including oncologists, scientists, biotech and pharmaceutical representatives, advocates, and patients, to discuss lifesaving cancer research at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 2 through June 6, 2023. The theme for this year’s conference, “Partnering With Patients: The Cornerstone of Cancer Care and Research,” was in recognition of…
Advocate Spotlight: Sydney Barned
Advocate Spotlight: Sydney Barned
Meet Dr. Sydney Barned, a lung cancer survivor-advocate from Jamaica who currently lives in Maryland.Sydney draws upon her unique experience as a physician and as a person living with lung cancer to help empower lung cancer patients and caregivers and to educate fellow healthcare providers and the public about the realities of lung cancer. Sydney is a doctor of internal medicine and a hospitalist. She was 33 years old and beginning her medical residency when she was unexpectedly diagnosed with…
dr Liu on the importance of NGS testing in NSCLC
Navigating Hope: How Comprehensive Biomarker Testing is Guiding Lung Cancer Care
Navigating Hope: How Comprehensive Biomarker Testing is Guiding Lung Cancer Care
Join us for a discussion on lung cancer biomarkers to learn what biomarker testing is, why it’s important, and how it can be used to optimize your treatment plans. We are thrilled to welcome our panelists: Balazs Halmos, MD, a thoracic medical oncologist from Montefiore Medical Center in New York; Elizabeth Ravera, a patient navigator at Montefiore; and a patient living with lung cancer who tested positive for the ALK biomarker. The panel is moderated by LUNGevity's Amy Moore, PhD, VP of Global…
Tracing the Clues of a Global Killer: How Dr. Charles Swanton’s Research Is Shedding New Light on Lung Cancer
Tracing the Clues of a Global Killer: How Dr. Charles Swanton’s Research Is Shedding New Light on Lung Cancer
As Chief Investigator of the groundbreaking Cancer Research UK (CRUK) TRACERx study, you could say that Dr. Charles Swanton is having a moment. Launched nine years ago, TRACERx seeks to understand lung cancer at its most basic level, “tracing” the clues that may predict how it starts and eventually changes over time so that doctors can treat it better.Collecting comprehensive genomic and clinical data from over 800 people with non-small cell lung cancer (NSCLC), Dr. Swanton and a team of over…
ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma
ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma
The safety and efficacy for the treatment of alectinib in a women with ALK-positive lung cancer delivered a healthy male neonate throughout Pregnancy: A case report
The safety and efficacy for the treatment of alectinib in a women with ALK-positive lung cancer delivered a healthy male neonate throughout Pregnancy: A case report
Caregiver Spotlight: Myra Aldarondo
Caregiver Spotlight: Myra Aldarondo
In the spring of 2021, Myra’s husband Kelvin had COVID-19. After, he had a lingering cough and shortness of breath. His chest hurt a bit when he breathed. They assumed it was pneumonia or at least COVID-related. They never guessed it would be lung cancer.Myra’s sister is a nurse, and she urged them to get an x-ray. They went to urgent care. After reviewing the scan, the doctor told them, “I can’t let you go home. You need to go to the emergency department and get a CAT scan right now. I can’t…
Survivor Spotlight: Randi Young and Sharon Schneider Found Their Footing with Team LUNGevity
Survivor Spotlight: Randi Young and Sharon Schneider Found Their Footing with Team LUNGevity
Team LUNGevity attracts experienced athletes, newcomers, and everyone in between. Many run, bike, or swim in honor or in memory of someone diagnosed with lung cancer, but lung cancer patients and survivors participate as well. Randi Young and Sharon Schneider are living with lung cancer and have recently completed their first races with Team LUNGevity. Both women have their own history with the sport, but each has found healing and renewed satisfaction by achieving their goals with Team…
What the End of the COVID Public Health Emergency Means for You
What the End of the COVID Public Health Emergency Means for You
It’s been more than 3 years since the US Department of Health and Human Services (HHS) first declared a nationwide Public Health Emergency (PHE) due to COVID-19. Since then, periodic renewals of the PHE have increased the flexibility of healthcare delivery. The PHE is set to end on May 11, 2023. A separate National Emergency that was enacted due to COVID-19 ended on April 10. Of the two, the end of the PHE will be more consequential for day-to-day healthcare delivery. This blog is a look back…
10 Reasons to Attend LUNGevity’s HOPE Summit
10 Reasons to Attend LUNGevity’s HOPE Summit
HOPE Summit is a weekend conference unlike any other! The Summit brings hundreds of people affected by lung cancer together to build their community, give and get support, and learn how to live well with lung cancer.As returning participant Tom puts it, “Imagine a world where you can look around and see hundreds of people thriving with lung cancer. Imagination is not necessary! Join us at the LUNGevity Summit on May 5th and celebrate life!” The conference takes place Friday, May 5 – Sunday, May…
Tackling the Biggest Challenges in Cancer
Tackling the Biggest Challenges in Cancer
Cancer Grand Challenges is a partnership between Cancer Research UK (CRUK) and the National Cancer Institute (NCI), which funds global teams of leading researchers across various scientific disciplines to tackle some of the toughest challenges in cancer research. As Dinah Singer, Acting Director of NCI’s Center for Strategic Scientific Initiatives says, “Cancer research is a global endeavor.” As LUNGevity’s Vice President of Global Engagement and Patient Partnerships, I recently attended the…
Let Your Voice Be Heard!
Let Your Voice Be Heard!
We are collecting stories from patients, caregivers, friends, and family members! Tell us how lung cancer has affected your life. Email your story to us at support@lungevity.org. Thanks!
Finding Clinical Trials for Lung Cancer: Tools and Resources
Finding Clinical Trials for Lung Cancer: Tools and Resources
Clinical trials are an important option for patients because the newest treatment approaches, not available otherwise, are being tested in them. Clinical trial research leads to more advancements and potential treatment options, and the therapies used today were once tested in clinical trials. Continued progress is only possible if patients with lung cancer volunteer to participate in the clinical trial process.
There are many ongoing clinical trials testing new lung cancer treatments,…
Fuel for the Future: Good Nutrition for the Lung Cancer Community
Fuel for the Future: Good Nutrition for the Lung Cancer Community
Learn valuable information about good nutrition that can help you live well through lung cancer treatment and beyond.
Gain insight and tips from Oncology Dietitian Lori Bumbaco, MS, RDN, CSO, as she shares her expertise in an interactive presentation and answers nutrition questions from the community. Then watch a live cooking demo, where Lori prepares a healthy meal and snack and shares recipe ideas and cooking tips. You’ll also hear about additional support programs and resources for the…
Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital
Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital
Real-World Drug Development at the Targeted Therapies of Lung Cancer Meeting
Real-World Drug Development at the Targeted Therapies of Lung Cancer Meeting
The development of new treatments for any disease relies on the collaborative efforts of many different stakeholders, such as scientists, clinicians, patient advocacy groups, regulators, and pharmaceutical and biotech companies.
During scientific conferences that happen throughout the year, stakeholders cobble together opportunities to discuss the current state of treatments and strategize ways to bring emerging lifesaving treatments to patients.
Each year, there is one key conference…